start
decemb
rapidli
spread
across
world
caus
widespread
concern
worth
note
definit
sex
differ
morbid
mortal
accord
recent
data
chines
center
diseas
control
prevent
cdc
ratio
male
infect
femal
infect
reach
among
patient
china
morbid
casefat
rate
cfr
women
significantli
lower
men
death
found
male
femal
mortal
rate
women
age
averag
menopaus
age
even
lower
result
indic
femal
less
suscept
male
better
outcom
sarscov
mer
sister
also
show
sex
prefer
infect
human
male
experienc
higher
cfr
compar
femal
shown
receptor
sarscov
interestingli
express
male
lung
femal
lung
consist
express
downregul
estrogen
confirm
anim
experi
show
estrogen
mitig
suscept
sever
phenotyp
sarscov
ovariectomi
intervent
estrogen
receptor
inhibitor
increas
mortal
femal
mice
antiviru
drug
studi
show
estrogen
receptor
inhibitor
possess
great
potenc
antivir
activ
screen
merscov
sarscov
rna
viru
also
antiebola
viru
effect
mice
studi
suggest
might
play
protect
role
sarscov
merscov
infect
lower
suscept
sever
better
outcom
correspond
diseas
howev
effect
sex
hormon
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
relat
menstruat
statu
progress
outcom
remain
unknown
attempt
address
question
enrol
patient
tongji
hospit
mobil
cabin
hospit
describ
found
sex
differ
sever
outcom
diseas
also
show
good
correl
menstruat
statushormon
level
sever
outcom
final
examin
associ
cytokin
relat
immun
inflamm
diseas
sever
clinic
outcom
learn
invers
correl
level
cytokin
result
demonstr
better
clinic
outcom
femal
patient
well
correl
menstruat
statu
femal
hormon
level
inquir
telephon
followup
menstrual
statu
gynecolog
histori
patient
final
includ
correl
menstruat
statu
diseas
sever
outcom
analyz
also
test
serum
cytokin
relat
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
immun
inflamm
femal
sex
hormon
level
femal
patient
except
deni
request
flowchart
studi
shown
serum
folliclestimul
hormon
fsh
lutein
hormon
lh
estradiol
testosteron
prolactin
prl
progesteron
p
level
measur
use
chemoluminescencebas
immunometr
assay
uniceldxi
immunoassay
system
beckman
coulter
inc
california
usa
serum
concentr
amh
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
measur
use
elecsi
amh
kit
roch
inc
basel
switzerl
sampl
measur
laboratori
intraand
interassay
coeffici
variat
lowest
amount
amh
could
detect
probabl
sampl
ngml
studi
review
approv
medic
ethic
committe
tongji
hospit
huazhong
univers
scienc
technolog
oral
inform
consent
obtain
enrol
patient
trial
regist
chines
clinic
trial
registri
continu
variabl
express
mean
standard
deviat
median
interquartil
rang
iqr
appropri
categor
variabl
summar
count
percentag
categori
mannwhitney
u
test
appli
continu
variabl
chisquar
test
fisher
exact
test
use
categor
variabl
appropri
multivari
cox
proport
hazard
model
use
evalu
independ
effect
menstruat
regular
prolong
hospit
time
control
age
sever
comorbid
multipl
logist
regress
model
use
assess
independ
adjust
relationship
menstruat
regular
diseas
sever
control
age
level
pearson
correl
analysi
use
explor
relationship
cytokin
relat
immun
inflamm
analys
conduct
spss
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
softwar
version
r
softwar
version
p
consid
signific
data
analyz
statistician
explor
sex
differ
sever
outcom
cohort
patient
infect
recruit
three
branch
tongji
hospit
femal
patient
mild
group
male
femal
approxim
proport
femal
male
patient
sever
group
male
femal
less
femal
patient
critic
group
male
femal
p
end
mar
femal
patient
male
patient
discharg
less
femal
patient
male
patient
die
p
signific
differ
male
femal
patient
sever
clinic
outcom
age
distribut
etabl
efigur
result
indic
femal
patient
rel
milder
better
outcom
accord
recent
publish
articl
patient
tongji
hospit
mobil
cabin
hospit
classifi
nonsever
group
sever
group
accord
american
thorac
societi
guidelin
communityacquir
pneumonia
admiss
publish
articl
nanshan
zhong
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
determin
correl
menstruat
diseas
progress
patient
offer
complet
menstruat
histori
includ
last
month
patient
regular
menstrual
cycl
patient
irregular
menstrual
cycl
shorter
longer
day
patient
enter
menopaus
amenorrhea
one
year
nonsever
group
patient
differ
menstruat
statu
regular
irregular
menopaus
respect
sever
group
proport
regular
irregular
decreas
respect
proport
menopaus
increas
etabl
age
consid
adjust
variabl
signific
reduc
p
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
irregular
group
p
menopaus
group
etabl
even
regular
irregular
group
merg
one
nonmenopaus
group
etabl
howev
discharg
use
endpoint
variabl
includ
comorbid
diseas
sever
age
menstruat
nonmenopaus
menopaus
brought
multivari
cox
regress
analysi
menstruat
show
definit
protect
effect
patient
nonmenopaus
tend
lower
hospit
proport
time
pass
discharg
earlier
patient
menopaus
control
age
sever
rel
hazard
rh
confid
interv
ci
etabl
figur
baselin
clinic
characterist
patient
agre
test
serum
hormon
shown
etabl
age
phase
menstrual
cycl
menstrual
regular
last
month
menstrual
volum
last
month
similar
term
sever
composit
end
point
correl
sex
hormon
diseas
sever
shown
tabl
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
tabl
correl
cytokin
relat
immun
inflamm
diseas
sever
composit
end
point
analyz
shown
etabl
higher
level
found
sever
group
nonsever
group
p
figur
etabl
higher
level
also
observ
patient
composit
end
point
patient
without
composit
end
point
etabl
signific
correl
amh
level
cytokin
found
studi
correl
level
either
luteal
follicular
phase
level
cytokin
shown
figur
tabl
figur
etabl
collect
level
posit
correl
sever
composit
endpoint
level
neg
correl
luteal
phase
follicular
phase
remain
incomplet
understood
sex
might
significantli
impact
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
outcom
patient
studi
indic
proport
sever
patient
less
femal
male
addit
clinic
outcom
femal
patient
better
male
patient
accord
recent
studi
appar
sexual
dimorph
account
differ
sever
outcom
infecti
diseas
femal
male
previou
studi
indic
menstruat
statu
hormon
fluctuat
may
affect
diseas
symptom
sever
studi
present
show
menstrual
cycl
volum
associ
clinic
sever
outcom
age
consid
adjust
variabl
signific
reduc
even
regular
irregular
group
merg
one
nonmenopaus
group
interestingli
postmenopaus
patient
longer
length
hospit
stay
nonmenopaus
femal
consid
age
sever
accordingli
psychiatr
hospit
women
significantli
greater
within
day
last
menstrual
period
normal
menstruat
regular
may
import
protect
factor
patient
howev
menstruat
often
affect
mani
factor
medic
environ
anxieti
asid
period
fluctuat
sex
hormon
sexspecif
diseas
outcom
follow
viru
infect
attribut
sexdepend
product
steroid
hormon
differ
copi
number
immun
respons
xlink
gene
presenc
diseas
suscept
gene
male
femal
data
show
amh
posit
correl
diseas
sever
primarili
produc
ovari
consid
preval
potent
form
circul
estrogen
estrogen
thought
protect
nonmenopaus
women
hepat
c
viru
pathogen
also
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
ovariectom
estrogen
receptor
antagonist
treat
femal
mice
suscept
sarscov
may
due
protect
effect
estrogen
receptor
signal
sarscov
infect
amh
chang
slightli
menstrual
cycl
drug
serv
optim
marker
ovarian
reserv
function
amh
level
posit
associ
number
oocyt
retriev
ovarian
respons
testosteron
logist
regress
analys
show
level
amh
nonsever
group
higher
sever
group
may
play
vital
role
progress
studi
nonsever
femal
higher
level
testosteron
sever
patient
previou
studi
shown
testosteron
suppress
effect
immun
system
cytokin
product
lymphocyt
prolifer
howev
adjust
age
signific
becam
unobvi
diseas
progress
testosteron
may
work
suppress
immun
storm
result
also
indic
stronger
protect
effect
potenti
neg
effect
testosteron
previou
studi
suggest
high
dose
may
inhibit
product
inflammatori
cytokin
eg
wherea
stimul
physiolog
level
enhanc
product
viral
infect
proinflammatori
cytokineschemokin
secret
macrophag
induc
variou
antivir
mechan
sever
clinic
studi
report
level
proinflammatori
cytokineschemokin
includ
highli
increas
patient
sar
correl
ard
respiratori
syncyti
viru
infect
human
infect
avian
influenza
virus
studi
level
neg
relat
diseas
sever
composit
end
point
relat
composit
end
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
point
consist
recent
studi
also
shown
regul
host
immun
respons
result
indic
neg
associ
follicular
phase
studi
sever
limit
first
correl
analysi
show
neg
correl
sever
causal
relationship
remain
unclear
second
serum
level
blood
sampl
regardless
phase
menstrual
cycl
result
may
complet
reflect
averag
level
effect
order
allevi
error
divid
menstrual
cycl
follicular
luteal
phase
analyz
third
sampl
size
serum
sex
hormon
might
larg
enough
sampl
need
determin
relationship
level
outcom
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
summari
data
reveal
sexbia
exist
patient
femal
less
sever
better
outcom
male
probabl
extent
due
protect
role
nonmenopaus
sex
hormon
especi
regul
cytokin
relat
immun
inflamm
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
funder
role
design
conduct
studi
collect
manag
analysi
interpret
data
prepar
review
approv
manuscript
decis
submit
manuscript
public
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
final
includ
test
serum
cytokin
relat
immun
inflamm
femal
sex
hormon
level
femal
patient
except
deni
request
final
determin
correl
menstruat
statussex
hormon
prognosi
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
univari
cox
regress
age
probabl
hospit
b
univari
cox
regress
menstruat
statu
probabl
hospit
menstruat
statu
divid
nonmenopaus
regular
irregular
menopaus
c
univari
cox
regress
diseas
sever
probabl
hospit
multivari
cox
analysi
covari
age
menstruat
sever
signific
p
howev
covari
comorbid
fail
signific
p
greater
hazard
ratio
menstruat
indic
strong
relationship
nonmenopauseand
decreas
risk
day
hospit
hazard
ratio
age
severityi
respect
indic
age
sever
huge
impact
risk
day
hospit
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
tnf
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
